Equitable Access for Pharma in Emerging Markets and LMICs
Unveiling the next chapter of the Pharma growth story
Pharmaceutical companies often face criticism for disproportionately prioritizing new drug launches in high-income countries, while simultaneously neglecting the promotion of equitable healthcare in LMICs. Yet, these regions offer immense growth potential and a chance to promote global healthcare equity while fulfilling pharma ESG target commitments. How to solve this struggle?
In our upcoming webinar, we explore arguments supporting equitable drug access, providing valuable insights into the vast untapped potential of emerging markets and showcasing successful strategies adopted by leading pharmaceutical companies worldwide. Participants can anticipate gaining knowledge in four key areas:
